Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- A trio of respiratory viruses is sending people to the hospital in N.J.
- He made his brothers get their arteries checked. Each had advanced heart disease.
- Yibin Kang’s team identifies new path to potential cancer treatments.
- Why a Life-Threatening Sedative Is Being Prescribed More Often for Seniors.
- NJACTS Community Engagement Core Available Services
Categories
- Community (2,445)
- Covid (997)
- CTO Events (6)
- News (3,098)
- Pilots (21)